|
Bayer Reports Positive Phase III Results for Potential Stomach Cancer Drug
Bayer HealthCare is planning on filings this year for regorafenib after Phase III success in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed after treatment with Novartis’ imatinib and Pfizer’s sunitinib.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives